Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Conjugate

Clinical Trial Description

This protocol has been updated following Protocol Amendment 1 date 26 July 2011 leading to the update of enrollment, a secondary outcome measure, intervention and exclusion criteria sections. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05929651` - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy	Phase 4
Completed	`NCT01543087` - Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose	Phase 3
Completed	`NCT01442675` - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine	Phase 2
Completed	`NCT00359983` - Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB	Phase 3
Recruiting	`NCT06128733` - Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents	Phase 1/Phase 2
Completed	`NCT00715234` - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients	N/A
Completed	`NCT01359449` - Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations	Phase 3
Recruiting	`NCT04843111` - Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
Completed	`NCT01890759` - Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation	Phase 3
Completed	`NCT01086969` - A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India	Phase 3
Completed	`NCT00700635` - Dose Comparison Study of Menactra® in US Children	Phase 2
Completed	`NCT00310635` - Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age	Phase 4
Completed	`NCT01659996` - Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age	Phase 4
Completed	`NCT00345683` - Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.	Phase 3
Completed	`NCT00392808` - Immunogenicity of the Booster Dose of Two MenC Vaccines	Phase 4
Completed	`NCT00258856` - Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®	Phase 2
Completed	`NCT00806195` - Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants	Phase 3
Completed	`NCT00269477` - Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®	Phase 2
Completed	`NCT00643916` - Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age	Phase 2
Completed	`NCT01049035` - A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers	Phase 2

NCT number	NCT01340898
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	January 27, 2012
Completion date	October 19, 2015

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms